believe progress joining great for our everyone, today's drug edasalonexent therapy dystrophy. and you, happy I'm be company muscular the months. made for will candidate Thank us over clinical by has to We Duchenne foundational three call. share past patients Good thank a you all that very affected morning, for the the Andrea.
disease to limited different the inhibit mechanism Catabasis all program, not mutations. will familiar therefore was call a are to Edasalonexent I with overview. the Duchenne. who on process those patients give potential approach and a treating less and is with a with patients the taking specific to to benefit For At are NF-kappa-B designed quick our we
to It Duchenne the is in to necessary protein important symptomatic remember boys couple that is of are young drive the not with Duchenne of not absence progression. in but Typically, their dystrophin disease years. first sufficient
activities NF-kappa-B, However, without skeletal progressive deterioration dystrophin from leads activates which everyday like mechanical to chronically stress of running, muscle.
in disease also as of the regardless a therapies. in as a Importantly, factor and is all benefit cardiac in combination as monotherapy targeted we both mutation, of critical edasalonexent bone inhibiting activation of NF-kappa-B, patients chronic component Duchenne dystrophin NF-kappa-B believe health Duchenne. can with well By
inhibiting benefit of the bone has to potential muscles Based action NF-kappa-B, cardiac the data including mechanism on skeletal clinical and and the health. also diaphragm our edasalonexent function,
of provider we enrollment announced that out family Polaris is which the for DMD edasalonexent. in was for our September, about point Duchenne affected exceeded, I Phase result In boys Duchenne. that to completed by trial I want target enrollment believe was excitement X
this shortly. talk will about Joanne, more
are in XXXX. that have the we of for an intended to expect data application The this from efforts edasalonexent pivotal commercial and fourth Now enrollment and support top line with CMC have non-clinical study is refined registration to along our quarter XXXX. completed, timeline ongoing our results in we in of clinical activities
design to to-date regulatory for continues We the X development our have seen months, to full have approval. filings global and As of for we ultimately regulatory the the data Phase action in Duchenne confident several landscape mechanism we of trial feel past evolve. a of the generated in the and support edasalonexent,
endpoint. primary uses reflect clinically the trials as Star activities Changes for the is a North North a the The pivotal daily meaningful Phase placebo Our in guidance. per endpoint X in trial Star assessment FDA Star changes controlled appropriate functional North of Ambulatory life.
I've are a laying progress next previously the foundation for of company. the mentioned, clinical our also stage strong As, activities, while we we
strengthened Komjathy with team the for We subject Duchenne. for addition of commercialization our He the prepare as as have we commercial Officer Chief edasalonexent his of initial our Andrew of impressions treatment the of the edasalonexent regulatory approval. to for opportunity share Commercial will
NF-kappa-B activated Miyoshi role entered into potential disease key both which myopathy. the Limb-girdle progression. Dysferlinopathy, dystrophy has in We Foundation other preclinical muscular forms to dystrophy, provide study, a collaboration type to benefit of Edasalonexent plays in the edasalonexent in includes muscular Jain where recently and a with XB
expect provide more this will of half work. preclinical Andy from in results collaboration details first XXXX. these We this on the
let an clinical Joanne our our Joanne? trials. provide I'll update Now, CMO on
